Allergan Inc. announced on Friday that it received the U.S. Food and Drug Administration approval to market Latisse, an eyelash-thickening medicine.

This beauty treatment was designed to treat hypotrichosis, a condition of the eyelashes in which the patient has thin and few eyelashes.

The active ingredient in the medicine is bimatroprost, the same ingredient that is included in glaucoma treatment Lumigan, said the maker, which also produces Botox.

Latisse, which is scheduled to be launched in February, is a once-a-day prescription treatment that a patient spreads over the base of the upper eyelash with the help of a sanitary, not reusable applicator that must be used only once per eye, the global specialty pharmaceutical company said. However, if the treatment is brought to a standstill, eyelashes will increasingly return to their initial condition.

Latisse solution’s retail price will be $120 for a 30-day supply bottle for both eyes, according to Allergan. The company expects global peak sales of the drug to reach $500 million a year.

Adverse events caused by Latisse, which represents a structural prostaglandin analog, include eye redness, irritated eyes, on top of a darkening of the eyelid skin. Besides, it may also affect the iris, Allergan said.

Latisse is “the first and only science-based treatment approved by the FDA to enhance eyelash prominence as measured by increases in length, thickness and darkness of eyelashes,” Scott Whitcup, M.D., the company’s Executive Vice President of Research and Development, said in a press statement.